首页 › 基金 › Bain Capital Life Sciences Investors, LLC › CABA

Bain Capital Life Sciences Investors, LLC 对 CABA 的持仓历史

CABALETTA BIO INC · 医疗保健

Bain Capital Life Sciences Investors, LLC 在 Q3 2026 的 13F 申报中披露持有 CABA(CABALETTA BIO INC)21,209,188 股,市值约 US$40.7M,约占其申报组合的 2.80%,在其申报持仓中市值排名第 12 位。 Bain Capital Life Sciences Investors, LLC 最近 13 个申报季度中有 13 个季度披露了 CABA 持仓,最早可追溯至 Q3 2023。

最新持仓 (Q3 2026)21.21M 股
申报持仓市值$40.72M
组合权重2.80%
首次申报Q3 2023
最近变动增持
更新于2026-11-16

最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR

Bain Capital Life Sciences Investors, LLC 对 CABA 的持仓演变

Bain Capital Life Sciences Investors, LLC 于 Q3 2023 首次披露 CABA 持仓:2,000,000 股(约 US$30.4M)。 该持仓在 Q2 2026 达到峰值 17,241,445 股,市值约 US$53.6M。 在 13 次申报中,Bain Capital Life Sciences Investors, LLC 5 次增持、1 次减持、6 次保持不变。 最近一期申报(Q3 2026)显示持股 21,209,188 股、市值约 US$40.7M,环比增持 3,967,743 股。。 持仓曾出现大幅变动:Q3 2024 增持约 67% (随后一个季度股价下跌 52%)、Q2 2025 增持约 251% (随后一个季度股价上涨 54%)、Q2 2026 增持约 78% (随后一个季度股价下跌 38%)。

逐季持仓明细

季度股数金额变化
Q3 2023 2.00M $30.44M 新进
Q4 2023 2.00M $45.40M 持有
Q1 2024 1.62M $27.59M 减持
Q2 2024 1.65M $12.34M 增持
Q3 2024 2.76M $13.03M 增持
Q4 2024 2.76M $6.27M 持有
Q1 2025 2.76M $3.82M 持有
Q2 2025 9.68M $14.71M 增持
Q3 2025 9.68M $22.64M 持有
Q4 2025 9.68M $21.19M 持有
Q1 2026 9.68M $26.03M 持有
Q2 2026 17.24M $53.62M 增持
Q3 2026 21.21M $40.72M 增持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 CABA 与 13F 数据

CABA(CABALETTA BIO INC)属于医疗保健行业。我们追踪的基金中还有 33 只申报持有 CABA,申报仓位最大的包括:Cormorant Asset Management, LP (US$15.6M), Opaleye Management Inc. (US$12.0M), Propel Bio Management, LLC (US$3.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 CABA 的基金

查看 CABA 的全部基金持有人 →

常见问题

How long has Bain Capital Life Sciences Investors, LLC held CABA?

Bain Capital Life Sciences Investors, LLC has disclosed CABA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Bain Capital Life Sciences Investors, LLC's current position in CABA?

As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 21.21M shares of CABA (CABALETTA BIO INC), valued at $40.72M, representing 2.80% of its reported portfolio and ranking #12.

Has Bain Capital Life Sciences Investors, LLC been buying or selling CABA?

In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC increased its position in CABA. The position peaked in Q2 2026 at 17.24M shares.

Which other funds hold CABA?

Other major institutional holders of CABA include Cormorant Asset Management, LP, Opaleye Management Inc., Propel Bio Management, LLC, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.